Phase Ib/II study of buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma multiforme

Update Il y a 5 ans
Reference: EUCTR2013-003129-27

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

Phase Ib : To determine the MTD and/or RP2D of buparlisib + carboplatin in patients with recurrent GBM who have progressed after SoC (RT with TMZ in combination and adjuvant) regardless of PI3K pathway activation status. same objective with buparlisib + lomustine phase II : To assess anti-tumor activity of buparlisib + carboplatin combination in patients with recurrent GBM who have progressed after SoC regardless of PI3K pathway activation status. To assess anti-tumor activity buparlisib + lomustine combination compared to lomustine + placebo in patients with recurrent GBM who have progressed after SoC regardless the PI3K pathway activation


Inclusion criteria

  • recurrent glioblastoma multiform

Links